GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called utidelone capsule combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination helps patients live longer and controls the cancer…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 23:51 UTC
-
New hope for stomach cancer: targeted drug HLX43 enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called HLX43 in people with advanced stomach or gastroesophageal junction cancer. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. About 60 adults aged 18 to 75 will receive the treatment to see if it shrinks t…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug spevatamig takes on tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug, Spevatamig, in people with advanced stomach, pancreatic, or bile duct cancers that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose of Spevatamig alone, then testing it combined with chemotherapy or …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:46 UTC